FDA APPROVES GENENTECH’S HEMLIBRA® (EMICIZUMAB-KXWH) FOR HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS
– First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis based on an intra-patient comparison – – Only medicine that can be self-administered subcutaneously once weekly, every two weeks or every four weeks for hemophilia A with and without factor VIII inhibitors –